Haymaker Acquisition Corp V is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar Business Combination with one or more businesses.
Last trade$9.81
Day change-$0.0101 (-0.10%)
Day range$9.80 – $9.83
Volume8,358
Market cap$316M
OpenXNYS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
No ratio data was found for HYAC.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for HYAC, quarterly periods
Line item
Q1 FY2022 Mar 31, 2022
Q4 FY2021 Dec 31, 2021
Q3 FY2021 Sep 30, 2021
Q2 FY2021 Jun 30, 2021
Revenue
—
—
—
—
Cost of revenue
$0
$0
$0
$0
Gross profit
—
—
—
—
Selling, general and administrative
—
—
—
—
Research and development
—
—
—
—
Total operating expenses
$50K
$84.93K
$26.63K
$43.33K
Operating income
-$50K
-$84.93K
-$26.63K
-$43.33K
Interest expense
—
—
—
—
Income before taxes
$1.17M
-$1.18M
$3M
$13.24M
Income taxes
—
—
—
—
Net income
$1.17M
-$1.18M
$3M
$13.24M
Net income attributable to common shareholders
$939.59K
-$1.18M
$3M
$13.24M
EBITDA
-$50K
-$84.93K
-$26.63K
-$43.33K
Basic earnings per share
$0.03
-$0.05
$0.08
$1.22
Diluted earnings per share
$0.03
-$0.06
$0.08
$1.22
Recent news
Company coverage with links to the original publishers.
NEW YORK, May 24, 2022 (GLOBE NEWSWIRE) -- Haymaker Acquisition Corp. III (Nasdaq: HYAC) (“Haymaker” or the “Company”), a publicly traded special purpose acquisition company, today announced that its stockholders voted to approve the previously announced business combination (the “Business Combination”) with Biote, and the related proposals, at Haymaker’s special meeting held on May 24, 2022. A Form 8-K disclosing the full voting results has been filed with the Securities and Exchange Commission.
IRVING, Texas, March 22, 2022 (GLOBE NEWSWIRE) -- Biote, a high growth, differentiated medical practice-building business within the hormone optimization space, today announced record financial results for the fourth quarter and full year of 2021.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.